Chronic Bacterial and Viral Infections in Neurodegenerative and Neurobehavioral Diseases

Lab Med
May 2008
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7107574/

Saturday afternoon Q & A (2017 Conference) (LDN, low dose naltrexone)

The Use of LDN for Ophthalmic Conditions - Sebastian Denison, Pharm (2021 Conference) (LDN, low dose naltrexone)

This talk is about how they utilize LDN, their LDN protocol, and their outcomes and expectations. The information presented about humans can apply to animals as well.

Reclaim the Lives of Lupus Patients, A Unique Treatment Approach - Deanna Windham, DO (2021 Conference) (LDN, low dose naltrexone)

Infection - Stefanie Werner, NMD (2021 Conference) (LDN, low dose naltrexone)

Mold toxicity - Leonard Weinstock, MD (2021 Conference) (LDN, low dose naltrexone)

Atopic Dermatitis - Pamela Smith, MD, MS (2021 Conference) (LDN, low dose naltrexone)

Atopic dermatitis is a hereditary skin disorder, and the most common form of eczema. Dr. Smith reviews the pathophysiology and diagnostic criteria for atopic dermatitis, as well as some causes.

Mast Cell Activation Syndrome (MCAS) - Leonard Weinstock, MD (2021 Conference) (LDN, low dose naltrexone)

How to treat pathologic cell behaviors - Mark Cooper, PhD (hons) MRPharmS (2021 Conference) (LDN, low dose naltrexone)